查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1927405

慢性骨髓性白血病（CML）急变期治疗市场按治疗类型、治疗线、作用机制、给药途径、患者年龄组、最终用户和分销渠道划分 - 全球预测 2026-2032

Treatment of Blastic-Phase CML Market by Treatment Type, Therapy Line, Mechanism Of Action, Route Of Administration, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，急变期慢性骨髓性白血病(CML) 治疗市场价值为 7.8021 亿美元，预计到 2026 年将增长至 8.6897 亿美元，预计到 2032 年将达到 15.9443 亿美元，复合年增长率为 10.74%。

关键市场统计数据
基准年 2025 7.8021亿美元
预计年份：2026年 8.6897亿美元
预测年份 2032 1,594,430,000 美元
复合年增长率 (%) 10.74%

本书简明扼要、权威地介绍了慢性骨髓性白血病急变期的临床复杂性、治疗目标和治疗策略。

慢性骨髓性白血病急变期是这种传统慢性骨髓恶性肿瘤的一个严重且进行性的阶段。其特征是未成熟的髓系或淋巴係原始细胞快速增殖，以及临床复杂性显着增加。在此阶段，治疗目标从长期控制疾病转变为快速细胞减灭、血液学稳定，并在可能的情况下，过渡到根治性治疗，例如异体造血干细胞移植。治疗决策需要准确的分子和细胞遗传学特征分析、快速的多学科协作，以及在疗效和耐受性之间取得合理的平衡，同时还要考虑到许多患者的体弱程度和既往治疗史。

新的临床范式、精准诊断和适应性发展策略正在重塑各种治疗环境下急变期 CML 的治疗和管理。

由于精准医学的进步、分子诊断技术的改进以及对联合治疗的日益重视（旨在解决抗药性和疾病异质性问题），慢性骨髓性白血病（CML）急变期治疗格局正在发生变革性变化。标靶治疗的创新拓展了传统细胞毒性疗法以外的选择，而定序技术的进步使得早期发现新出现的抗药性突变成为可能，从而直接指导治疗顺序和临床试验设计。同时，免疫调节策略和新型单株抗体结构的整合正在改变人们对持久疾病控制的预期，尤其是在利用互补作用机制的合理联合治疗中。

2025年美国关税政策预期变化对急性增生期慢性骨髓性白血病治疗药物的供应链、采购经济性和策略性生产选择的影响

影响进口关税和贸易流量的政策变化可能对肿瘤药物的采购、定价和分销产生重大影响，而计划于2025年实施的关税调整方案需要慢性粒细胞白血病（CML）急变期生态系统中的相关人员认真考虑。原料药、生物製药中间体或成品药关税的提高可能导致医院、专科诊所和药品批发商的采购成本上升，进而可能对合约策略和预算分配造成压力。依赖全球供应链采购原料药和外包委託製造的製造商可能面临成本上涨的压力，这或许会迫使他们重新谈判供应商合约或转移生产。

基于深入的细分市场分析，揭示了治疗类型、治疗线、作用机制、给药途径、最终用户和分销管道对策略选择的影响。

细分市场层面的洞察揭示了治疗研发和商业策略应如何与临床实际情况和医疗服务路径相契合。根据治疗类型，联合治疗、单株抗体和小分子抑制剂的市场动态各不相同。联合治疗强调协同机制和安全性管理；单株抗体需要特殊的输注剂量和规模化生产的考量；而小分子抑制剂则受益于口服给药和成熟的生产平台。根据治疗线数，第一线、二线、三线及后续治疗阶段各自面临不同的挑战。第一线治疗优先考虑耐受性和持久疗效；二线治疗需平衡抗药性和先前用药情况；而后续治疗阶段则着重于挽救治疗和安宁疗护。

区域监管环境、支付方环境和供应链现状将如何影响美洲、欧洲、中东和非洲以及亚太地区的治疗取得和采用趋势

区域趋势对慢性骨髓性白血病（CML）急变期治疗的临床实践、支付方框架和准入途径有显着影响。在美洲，完善的研究基础设施、活跃的临床试验网络以及多元化的公私支付方将影响治疗方案的推广应用轨迹，而供应链集中度和监管要求将影响商业化时间表和报销谈判。跨境贸易模式和区域製造地也将影响全部区域医院和专科诊所的筹资策略和库存计划。

领先的疗法开发商正在推进其产品线并实现慢性骨髓性白血病（CML）急变期治疗药物的商业化，这影响着他们的企业策略、合作以及营运重点。

製药和生物技术公司的活动将继续围绕差异化产品线、策略合作和营运弹性展开，以应对慢性骨髓性白血病（CML）急变期特有的挑战。开发Bcr-Abl抑制剂的公司正在投资下一代化合物和伴随诊断，以克服抗药性并延长临床疗效；而免疫调节剂和单株抗体开发商则优先考虑可整合到现有治疗流程中的联合治疗。与契约製造组织（CMO）和专业分销商合作的重要性日益凸显，以确保供应的连续性并高效扩大生物製药的生产规模。

为开发商、供应商和支付方提供切实可行的、具有重大影响的建议，以协调慢性骨髓性白血病(CML) 急变期的临床创新、供应弹性和获取途径。

产业领导者应采取一系列综合行动，将临床创新与实际的药物取得和交付考量相结合。优先考虑包含分子分层、适应性检测要素以及与监管和报销相关人员早期沟通的研发策略，以缩短决策时间并加强证据支持。同时，应与医院、专科诊所和门诊中心合作，设计反映临床实际的商业模式，确保患者在接受治疗时能够获得输液基础设施、口服药物监测和支持性护理资源。

我们采用透明、专家主导的调查方法，结合与临床医生的直接对话、系统性的文献综合和迭代数据检验，确保我们获得可操作的见解。

本分析所依据的研究融合了定性和定量调查方法，从而提供了可靠且令人信服的证据基础。主要研究包括对临床专家、药房主任、支付方和供应链高管进行结构化访谈，以收集关于治疗决策、采购惯例和营运限制的第一手观点。此外，也透过对同侪审查文献、临床试验註册库和监管指导文件的系统性回顾，对临床疗效、安全性以及发展趋势进行背景分析。

本文简明扼要地总结了临床、营运和策略方面对相关人员的影响，旨在帮助他们将治疗进展转化为急性期慢性骨髓性白血病(CML) 治疗效果的改善。

总之，急变期慢性骨髓性白血病（CML）既带来了巨大的临床挑战，也蕴藏着治疗创新的巨大机会。精准诊断、新型标靶药物和联合治疗策略的融合正在为更有效的疾病控制铺平道路，但要充分发挥这一潜力，需要采取协作方式，解决临床异质性、供应链复杂性和支付方期望等问题。相关人员必须整合可靠的证据产生、灵活的监管参与和切实可行的准入计划，才能将科学进步转化为病人预后的改善。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8.慢性骨髓性白血病（CML）急变期治疗市场（依治疗方法划分）

  • 联合治疗
  • 单株抗体
  • 小分子抑制剂

9.慢性骨髓性白血病（CML）急变期治疗市场（依治疗线划分）

  • 一线治疗
  • 二级治疗
  • 第三线及以后

第十章慢性骨髓性白血病（CML）急变期治疗市场依作用机制划分

  • Bcr-Abl抑制剂
  • 化疗药物
  • 免疫调节剂

第十一章慢性骨髓性白血病（CML）急变期治疗市场（依给药途径划分）

  • 静脉注射
  • 口服

第十二章 依病患年龄组别分類的急变期慢性骨髓性白血病(CML) 治疗市场

  • 成人
  • 儿童

第十三章 急变异期慢性骨髓性白血病（CML）治疗市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 专科诊所

第十四章慢性骨髓性白血病（CML）急变期治疗市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十五章 各地区慢性骨髓性白血病（CML）急变期治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章慢性骨髓性白血病（CML）急变期治疗市场（按组别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国慢性骨髓性白血病（CML）急变期治疗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国急变期慢性骨髓性白血病（CML）治疗市场

第十九章 中国急变期慢性骨髓性白血病（CML）治疗市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bristol-Myers Squibb Company
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Novartis AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
Product Code: MRR-4F7A6D4FF3A3

The Treatment of Blastic-Phase CML Market was valued at USD 780.21 million in 2025 and is projected to grow to USD 868.97 million in 2026, with a CAGR of 10.74%, reaching USD 1,594.43 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 780.21 million
Estimated Year [2026] USD 868.97 million
Forecast Year [2032] USD 1,594.43 million
CAGR (%) 10.74%

A concise and authoritative introduction to the clinical complexity, therapeutic objectives, and strategic treatment context for blastic-phase chronic myeloid leukemia

Blastic-phase chronic myeloid leukemia represents a critical and aggressive phase of a traditionally chronic hematologic malignancy, characterized by rapid proliferation of immature myeloid or lymphoid blasts and a substantial escalation in clinical complexity. Therapeutic goals at this stage shift decisively from long-term disease management toward rapid cytoreduction, stabilization of hematologic function, and bridging patients to potentially curative interventions such as allogeneic hematopoietic stem cell transplantation where feasible. Treatment decisions require precise molecular and cytogenetic characterization, swift multidisciplinary coordination, and a pragmatic balance between efficacy and tolerability given the frailty and treatment history of many patients.

Recent years have underscored the heterogeneity within blastic-phase presentations, including variable responses to Bcr-Abl-directed therapies, emerging resistance mechanisms, and the intersection of comorbidities that influence regimen selection. Consequently, clinicians and health systems must integrate evolving diagnostic capabilities, adaptive clinical protocols, and supportive care frameworks to optimize outcomes. From a strategic perspective, pharmaceutical innovators face the dual imperatives of demonstrating clinical benefit in small, heterogeneous patient cohorts while developing practical delivery models that account for inpatient and ambulatory settings. Moving forward, harmonizing clinical evidence with operational readiness and payer expectations will be fundamental to translating therapeutic advances into measurable patient benefit.

Emerging clinical paradigms, precision diagnostics, and adaptive development strategies reshaping how blastic-phase CML is treated and managed across care settings

The therapeutic landscape for blastic-phase CML is experiencing transformative shifts driven by precision medicine advances, improved molecular diagnostics, and a growing emphasis on combination regimens that address resistance and disease heterogeneity. Innovations in targeted therapies have expanded options beyond traditional cytotoxic approaches, and improvements in sequencing technologies enable earlier detection of emergent resistance mutations that directly inform therapeutic sequencing and trial design. At the same time, the integration of immunomodulatory strategies and novel monoclonal antibody constructs has begun to alter expectations for durable disease control, particularly when used in rational combinations that exploit complementary mechanisms.

These scientific advances are paralleled by changes in clinical development and regulatory engagement. Adaptive trial designs, biomarker-stratified cohorts, and real-world evidence frameworks are increasingly leveraged to demonstrate efficacy and safety in smaller, more targeted populations. Meanwhile, health systems are adapting care pathways to accommodate oral targeted agents, outpatient infusion regimens, and enhanced supportive care services, which together influence adherence and patient experience. Taken together, these shifts underscore a broader reorientation: from single-agent, disease-centered approaches toward personalized, multimodal strategies that align molecular insights with pragmatic care delivery and value-based considerations.

How evolving United States tariff policies in 2025 could reshape supply chains, procurement economics, and strategic manufacturing choices across blastic-phase CML therapeutics

Policy changes affecting import tariffs and trade flows can materially influence the sourcing, pricing, and distribution of oncology therapeutics, and proposed tariff adjustments slated for 2025 merit careful consideration across stakeholders in the blastic-phase CML ecosystem. Increased tariffs on active pharmaceutical ingredients, biologic intermediates, or finished drug products can translate into higher procurement costs for hospitals, specialty clinics, and pharmacy distributors, which in turn may pressure contracting strategies and budget allocations. Manufacturers that rely on global supply chains for APIs or outsourced manufacturing may experience upward cost pressure that necessitates renegotiation of supplier agreements or revision of production footprints.

Moreover, altered tariff regimes can shape strategic priorities, prompting accelerated investment in domestic manufacturing capacity, nearshoring of critical production steps, or diversification of supplier networks to mitigate exposure. Health systems and payers may respond by intensifying formulary scrutiny, seeking value-based contracting arrangements, or prioritizing therapeutics with lower total cost of care profiles. For clinical programs and commercialization plans, tariff-induced uncertainties require scenario planning that accounts for procurement timelines, inventory management, and the potential need for phased launches or prioritized allocation during periods of constrained supply. In summary, the cumulative impact of tariff changes reaches beyond direct cost implications to influence supply resilience, pricing negotiations, and competitive dynamics across the treatment continuum.

Detailed segmentation-driven intelligence revealing how treatment type, therapy line, mechanism, administration route, end user and distribution channel influence strategic choices

Segment-level insights illuminate how therapeutic development and commercial strategies should be tailored to clinical realities and care delivery pathways. Based on Treatment Type, market dynamics differ across Combination Therapies, Monoclonal Antibodies, and Small Molecule Inhibitors, with combination approaches emphasizing synergistic mechanisms and safety management, monoclonal antibodies requiring specialized infusion and scale considerations, and small molecule inhibitors benefiting from oral administration and established manufacturing platforms. Based on Therapy Line, distinctive imperatives emerge across First Line, Second Line, and Third Line And Beyond, where first-line decisions prioritize tolerability and durable response, second-line selection balances resistance profiles and prior exposure, and later lines focus on salvage options and palliative control.

Based on Mechanism Of Action, therapeutic positioning varies between Bcr-Abl Inhibitors, Chemotherapy Agents, and Immunomodulators, with Bcr-Abl inhibitors targeting driver oncogenic signaling, chemotherapy agents delivering broader cytotoxic impact, and immunomodulators aiming to harness host immune responses to improve depth and durability of remission. Based on Route Of Administration, Intravenous and Oral pathways carry distinct implications for patient convenience, monitoring requirements, and site-of-care economics; oral agents can reduce inpatient resource use but demand adherence support, while intravenous therapies necessitate infusion infrastructure and may enable controlled administration of complex biologics. Based on End User, treatment delivery and procurement will differ for Ambulatory Surgical Centers, Hospitals, and Specialty Clinics as each setting maintains unique clinical capabilities, reimbursement profiles, and contracting practices. Based on Distribution Channel, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy present varied dispensing workflows, stock management priorities, and patient access modalities that influence channel strategy. Based on Patient Age Group, adults and pediatrics present distinct clinical trial design considerations, dosing strategies, and supportive care needs, underscoring the necessity for age-specific evidence generation and patient support programs.

How regional regulatory frameworks, payer landscapes, and supply chain realities across the Americas, Europe Middle East & Africa, and Asia-Pacific drive access and adoption dynamics

Regional dynamics exert a pronounced influence on clinical practice, payer frameworks, and access pathways for blastic-phase CML therapies. In the Americas, strong research infrastructures, active clinical trial networks, and a diverse mix of private and public payers shape adoption trajectories, while supply chain concentration and regulatory requirements influence commercialization timelines and reimbursement negotiations. Cross-border trade patterns and regional manufacturing hubs also affect procurement strategies and inventory planning for hospitals and specialty clinics throughout the region.

Europe, Middle East & Africa encompasses a broad spectrum of regulatory and reimbursement models, where national health technology assessment processes, centralized regulatory pathways, and variable healthcare budgets determine the pace and breadth of access. In some markets within these regions, established reference pricing and tendering mechanisms create competitive pressures that favor demonstrated value and cost-effectiveness, thereby shaping clinical adoption and local formulary decisions. Infrastructure constraints in several markets may prioritize scalable oral regimens and outpatient management strategies to maximize reach.

The Asia-Pacific region features rapid expansion of clinical research activity, increasing domestic manufacturing capacity, and a mix of mature and emerging payer systems. Rapidly growing demand for hematologic oncology care, paired with evolving reimbursement coverage and strategic public-private partnerships, positions the region as a pivotal arena for clinical trials and launch sequencing. Across all regions, local regulatory engagement, stakeholder education, and supply chain planning remain essential to achieving timely access and optimizing patient outcomes.

Corporate strategies, collaborations, and operational priorities shaping how leading therapeutic developers advance pipelines and commercialize blastic-phase CML treatments

Corporate behavior among pharmaceutical and biotechnology organizations will continue to center on pipeline differentiation, strategic partnerships, and operational agility to address the distinct challenges of blastic-phase CML. Companies advancing Bcr-Abl inhibitors are investing in next-generation compounds and companion diagnostics to overcome resistance and extend clinical durability, while developers of immunomodulatory agents and monoclonal antibodies prioritize combination regimens that can be integrated into existing treatment algorithms. Partnerships with contract manufacturing organizations and specialty distribution firms are increasingly prioritized to ensure supply continuity and to scale biologic production efficiently.

Competitive positioning also depends on strategic investments in clinical development design, including adaptive trials, biomarker-driven subgroup analyses, and expanded access initiatives that can generate early real-world evidence. Commercial strategy is informed by the need to demonstrate value to hospital systems and specialty clinics, supported by robust pharmacoeconomic evidence and targeted patient support programs that address adherence and access barriers. Ultimately, successful organizations will align scientific differentiation with pragmatic commercialization capabilities, leveraging cross-functional collaboration across clinical affairs, regulatory, market access, and supply operations to accelerate uptake and sustain long-term viability.

Actionable, high-impact recommendations for developers, providers, and payers to align clinical innovation, supply resilience, and access pathways for blastic-phase CML

Industry leaders should pursue an integrated set of actions that align clinical innovation with pragmatic access and delivery considerations. Prioritize development strategies that incorporate molecular stratification, adaptive trial elements, and early engagement with regulatory and reimbursement stakeholders to reduce time-to-decision and strengthen evidentiary packages. Simultaneously, design commercial models that reflect site-of-care realities by coordinating with hospitals, specialty clinics, and ambulatory centers to ensure that infusion infrastructure, oral therapy monitoring, and supportive care resources are available where patients receive treatment.

Invest in supply chain resilience by diversifying API and biologic sourcing, evaluating nearshoring or regional manufacturing partnerships, and enhancing inventory management systems to mitigate tariff and trade disruptions. Build payer and provider engagement programs that foreground total cost of care, real-world outcomes, and patient-reported measures to support value-based contracting and formulary inclusion. Expand patient support and adherence initiatives tailored to adult and pediatric populations to maximize therapeutic benefit, and integrate digital health solutions to monitor response and toxicities. Finally, foster cross-sector collaborations that combine diagnostic expertise, clinical networks, and commercial capabilities to accelerate uptake and ensure that therapeutic advances translate into meaningful improvements in patient care.

A transparent, expert-driven research methodology combining primary clinician engagement, systematic literature synthesis, and iterative data validation to ensure actionable insights

The research underpinning this analysis synthesizes qualitative and quantitative methodologies to provide a robust and defensible evidence base. Primary research comprises structured interviews with clinical experts, pharmacy directors, payers, and supply chain executives to capture frontline perspectives on treatment decision-making, procurement practices, and operational constraints. These insights are complemented by a systematic review of peer-reviewed literature, clinical trial registries, and regulatory guidance documents to contextualize clinical efficacy, safety profiles, and development trends.

Secondary data collection includes an assessment of published clinical outcomes, treatment guidelines, and policy analyses to inform thematic trends and treatment paradigms. Data validation is achieved through triangulation across sources and iterative review with subject matter experts to ensure consistency and practical relevance. Where appropriate, sensitivity analyses and scenario planning were employed to evaluate the implications of supply disruptions, policy shifts, and therapeutic innovation on clinical and commercial pathways. Limitations include variability in data availability for rare and heterogeneous patient subgroups and the evolving nature of clinical trial outcomes, which necessitate ongoing monitoring and periodic update cycles to maintain currency.

A concise synthesis of clinical, operational, and strategic implications for stakeholders aiming to translate therapeutic advances into improved outcomes for blastic-phase CML

In conclusion, blastic-phase CML presents both significant clinical challenges and clear opportunities for therapeutic innovation. The convergence of precision diagnostics, novel targeted agents, and combination strategies creates a pathway toward more effective disease control, but realizing this potential requires coordinated approaches that address clinical heterogeneity, supply chain complexity, and payer expectations. Stakeholders must integrate robust evidence generation, adaptive regulatory engagement, and pragmatic access planning to translate scientific advances into improved patient outcomes.

Forward-looking organizations will prioritize molecularly informed development, durable partnerships across manufacturing and distribution, and proactive payer engagement to secure access across diverse regional markets. By aligning clinical ambition with operational readiness, the field can advance beyond incremental gains and deliver tangible benefit to patients facing this aggressive phase of disease. Continuous monitoring of clinical evidence, policy shifts, and supply dynamics will remain essential to adapt strategies as new data and external conditions evolve.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Treatment of Blastic-Phase CML Market, by Treatment Type

  • 8.1. Combination Therapies
  • 8.2. Monoclonal Antibodies
  • 8.3. Small Molecule Inhibitors

9. Treatment of Blastic-Phase CML Market, by Therapy Line

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third Line And Beyond

10. Treatment of Blastic-Phase CML Market, by Mechanism Of Action

  • 10.1. Bcr-Abl Inhibitors
  • 10.2. Chemotherapy Agents
  • 10.3. Immunomodulators

11. Treatment of Blastic-Phase CML Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral

12. Treatment of Blastic-Phase CML Market, by Patient Age Group

  • 12.1. Adults
  • 12.2. Pediatrics

13. Treatment of Blastic-Phase CML Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Hospitals
  • 13.3. Specialty Clinics

14. Treatment of Blastic-Phase CML Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Treatment of Blastic-Phase CML Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Treatment of Blastic-Phase CML Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Treatment of Blastic-Phase CML Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Treatment of Blastic-Phase CML Market

19. China Treatment of Blastic-Phase CML Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Bristol-Myers Squibb Company
  • 20.6. Hikma Pharmaceuticals PLC
  • 20.7. Lupin Limited
  • 20.8. Novartis AG
  • 20.9. Pfizer Inc.
  • 20.10. Sandoz International GmbH
  • 20.11. Sun Pharmaceutical Industries Limited
  • 20.12. Takeda Pharmaceutical Company Limited
  • 20.13. Teva Pharmaceutical Industries Limited
  • 20.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY BCR-ABL INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY BCR-ABL INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GCC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. G7 TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. NATO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)